These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1753 related items for PubMed ID: 18486740

  • 1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators.
    Lancet; 2008 May 17; 371(9625):1675-84. PubMed ID: 18486740
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators.
    Lancet; 2008 May 17; 371(9625):1665-74. PubMed ID: 18486739
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA.
    Br J Dermatol; 2012 Apr 25; 166(4):861-72. PubMed ID: 22356258
    [Abstract] [Full Text] [Related]

  • 5. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
    Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, Davis HM.
    J Clin Pharmacol; 2010 Mar 25; 50(3):257-67. PubMed ID: 19934030
    [Abstract] [Full Text] [Related]

  • 6. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.
    N Engl J Med; 2015 Oct 25; 373(14):1318-28. PubMed ID: 26422722
    [Abstract] [Full Text] [Related]

  • 7. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M.
    Lancet; 2021 Feb 06; 397(10273):487-498. PubMed ID: 33549193
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators.
    Lancet; 2015 Aug 08; 386(9993):541-51. PubMed ID: 26072109
    [Abstract] [Full Text] [Related]

  • 9. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
    Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.
    Br J Dermatol; 2010 Jan 08; 162(1):137-46. PubMed ID: 19903183
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
    van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S.
    Lancet; 2018 Oct 13; 392(10155):1330-1339. PubMed ID: 30249507
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group.
    J Dermatol; 2012 Mar 13; 39(3):242-52. PubMed ID: 21955098
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
    Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators.
    J Eur Acad Dermatol Venereol; 2013 Dec 13; 27(12):1535-45. PubMed ID: 23279003
    [Abstract] [Full Text] [Related]

  • 13. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
    Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A.
    Lancet; 2009 Feb 21; 373(9664):633-40. PubMed ID: 19217154
    [Abstract] [Full Text] [Related]

  • 14. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 21; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 15. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, Ustekinumab MS Investigators.
    Lancet Neurol; 2008 Sep 21; 7(9):796-804. PubMed ID: 18703004
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 21; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
    Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators.
    Arch Dermatol; 2008 Feb 21; 144(2):200-7. PubMed ID: 18283176
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM.
    Lancet; 2012 Aug 25; 380(9843):738-46. PubMed ID: 22748702
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
    McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, PSUMMIT 1 Study Group.
    Lancet; 2013 Aug 31; 382(9894):780-9. PubMed ID: 23769296
    [Abstract] [Full Text] [Related]

  • 20. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, Kerkmann U, Ghislain PD, Poulin Y, PHOENIX 1 investigators.
    Br J Dermatol; 2014 Feb 31; 170(2):398-407. PubMed ID: 24117389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 88.